B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due
to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted …

The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric
antigen receptor modified T cells and bispecific antibodies are bringing new treatment …

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we
created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to …

Immunomodulatory drugs (IMiD) are a backbone therapy for multiple myeloma (MM).
Despite their efficacy, most patients develop resistance, and the mechanisms are not fully …

Targeted protein degradation using proteolysis-targeting chimeras (PROTACs) has
emerged as an effective strategy for drug discovery, given their unique advantages over …

The complex architecture of transmembrane proteins requires quality control (QC) of folding,
membrane positioning, and trafficking as prerequisites for cellular homeostasis and …

Angioimmunoblastic T‐cell lymphoma (AITL) is a common type of peripheral T‐cell
lymphoma (PTCL) with a poor prognosis, and an effective first‐line therapy is lacking …

CD38 is highly expressed on multiple myeloma (MM) cells and plays a role in regulating
tumor generation and development. CD38 monoclonal antibodies (mAbs) have been used …

Abstract Background Acquired von Willebrand syndrome (AVWS) has been associated with
monoclonal gammopathy of undetermined significance (MGUS), with limited data on its …

Simple Summary Due to the complex mechanism of actions, immunomodulatory drugs
(IMiDs) are one of the primary drug classes used to treat multiple myeloma (MM). IMiDs are …